Lauxera Capital Partners

OrganOx is a medical device company focused on organ preservation and transplantation, specializing in normothermic preservation technology that mimics physiological conditions to protect livers before transplantation. The company develops and manufactures systems that continuously perfuse livers at body temperature with oxygenated blood, nutrients, and controlled pressures and flows to reduce decay, support bile production, glucose metabolism, and pH stability. Its Metra device stores livers outside the body at normal body temperature, enabling testing and transplantation. OrganOx was founded in 2008 and is based in Oxford, United Kingdom. The technology aims to improve transplant outcomes by maintaining organ viability during storage and enabling more flexible transplantation timelines.

Acandis develops and manufactures innovative medical devices for treating neurovascular diseases. Their product portfolio includes stroke solutions like Flow Diverters, Stent Retrievers, and Embolisation Devices, focusing on acute stroke care and thrombectomy.

Synovo Group specializes in digital services for medical transport professionals. They offer a range of solutions including hosting, infrastructure management, cloud services, telecom support, and security consultancy, ensuring compliance with health data standards.

Natural Cycles is a digital health company that provides a contraceptive app aimed at enhancing women's reproductive health. The app allows users to track their basal body temperature daily, using a specialized thermometer to input data. This information, combined with other relevant metrics, is analyzed through a proprietary algorithm to determine fertility status throughout the menstrual cycle. The app features a color-coded calendar that informs users about their fertile days, helping them decide when they can have unprotected sex. By offering a non-invasive, non-hormonal method of fertility tracking, Natural Cycles empowers women to take control of their reproductive health and make informed decisions about family planning.

BioLamina specializes in the development and distribution of laminin-based cell culture products worldwide. Its portfolio includes defined human recombinant laminin matrices, designed to support the growth and maintenance of various cell types, including stem cells and tissue-specific cells. BioLamina's products cater to applications such as human ES cell culturing, mouse ES cell culturing, beta cell-islets creation, and single cell ES cell culturing.

OrganOx is a medical device company focused on organ preservation and transplantation, specializing in normothermic preservation technology that mimics physiological conditions to protect livers before transplantation. The company develops and manufactures systems that continuously perfuse livers at body temperature with oxygenated blood, nutrients, and controlled pressures and flows to reduce decay, support bile production, glucose metabolism, and pH stability. Its Metra device stores livers outside the body at normal body temperature, enabling testing and transplantation. OrganOx was founded in 2008 and is based in Oxford, United Kingdom. The technology aims to improve transplant outcomes by maintaining organ viability during storage and enabling more flexible transplantation timelines.

Matrix Requirements is a global software company specializing in quality management solutions for innovative medical device manufacturers. Its flagship products, MatrixALM and MatrixQMS, help streamline regulatory processes by integrating agile development with compliance, ensuring product quality throughout the lifecycle.

Veranex is a global service provider that specializes in the medical technology sector, offering comprehensive, technology-enabled solutions from concept to commercialization. The company focuses exclusively on various areas within medical technology, including medical devices, diagnostics, companion diagnostics, digital health, and drug delivery. Veranex provides a wide range of services, such as design and engineering, regulatory support, clinical trials, and market access, enabling clients to streamline their development processes. By addressing the entire clinical trial journey, Veranex helps clients accelerate their time to market, enhance market viability, manage development costs, and reduce associated risks.

Founded in Paris in 2015, Lifen is a leading provider of digital health solutions in France. With over 600 partner establishments, it facilitates secure sharing of medical data among hospitals, doctors, and patients. Lifen's platform sends around 2 million documents monthly to approximately 240,000 healthcare practitioners. Recognized for its expertise in interoperability, the company aims to simplify technical integration and deployment of digital solutions.

Groupe PSIH provides healthcare data hosting and management services for managing activities of hospitals.

Caresyntax develops a digital surgery platform that improves patient outcomes by analyzing large volumes of data from operating rooms. Its proprietary software and AI enable OR teams to predict and enhance surgical performance, helping surgeons benchmark their care, hospital administrators optimize resources, medical device companies advance products, and insurance providers assess risk.

LUMICKS develops innovative technologies for studying biology and cancer at single-molecule and single-cell levels. Its products include C-Trap Optical Tweezers, Fluorescence Microscopy, and z-Movi Cell Avidity Analyzer, enabling real-time analysis of complex biological processes and interactions.

Reapplix is a Danish medical technology company that develops autologous wound therapy and tissue regeneration solutions derived from the patient's blood. It identifies and isolates blood-derived proteins to accelerate healing of chronic wounds and markets a device capable of delivering autologous active cell therapy to treat diabetic foot ulcers, with the aim of improving healing outcomes and reducing treatment costs. Founded in 2008 and based in Birkerod, Denmark, the company focuses on enabling hospitals to provide biological wound treatment using the patient's own cells.